MedTrace Logo

TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast)

NCT03096327 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2018-07-09

No results posted yet for this study

Summary

• To compare the quality of Life using AQLQ (s) questionnaire after 4 weeks of Montelukast.

Conditions

Interventions

DRUG

Montelukast

Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.

DRUG

Placebo

Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured

Sponsors & Collaborators

  • PharmEvo Pvt Ltd

    lead INDUSTRY

Principal Investigators

  • Masood Jawaid, MRCS,FCPS · PharmEvo Pvt Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2017-12-30
Completion
2018-05-30

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096327 on ClinicalTrials.gov